ANDHealth has today announced the appointment of health technology leader Sergio Duchini to its Board in the role of Non-Executive Director.

Mr Duchini is an experienced Chair and Non-Executive Director across the biotechnology and health technology sectors, bringing extensive expertise in governance, capital markets, and R&D commercialisation and strategy.  

He currently serves as Chair of Neurizon Therapeutics Limited, which is dedicated to revolutionising the treatment of neurodegenerative diseases, Non-Executive Director and Chair of the Audit & Risk Committee at Enlitic Limited, which is focused on transforming medical imaging through AI, and Non-Executive Director and Chair of the Audit & Risk Committee at QBiotics Group Limited, which is delivering innovative, nature-inspired therapeutics in human and veterinary health.

With a career spanning nearly three decades, including 23 years as a Partner and more than seven years as a Board Member at Deloitte Australia, and more than 15 years of board-level experience, Mr Duchini has advised a broad range of organisations on strategy, innovation, and commercialisation. He is a member of the Medicines Australia Advisory Council, a member of the R&D Incentives Committee at the Department of Industry, Science and Resources, and a former Board member of AusBiotech.

Commenting on his appointment, Mr Duchini said he is excited to contribute to the next stage of ANDHealth’s growth and impact.

“ANDHealth plays a critical role in unlocking the potential of Australia’s digital and connected health sector. I look forward to supporting its mission to accelerate the commercialisation of technologies that deliver meaningful clinical and commercial impact for patients and the health and care system.”

ANDHealth Chair Gavin Fox-Smith said Mr Duchini’s extensive experience across the health innovation landscape and deep understanding of commercial and governance frameworks will be of significant value to the organisation.

“Sergio’s broad experience across both the private and public sectors, combined with his strategic insight and commercial acumen, will be an enormous asset as ANDHealth continues to build on its success accelerating the commercialisation and uptake of evidence-based digital and connected health technologies, products and services.”

ANDHealth Chief Executive Bronwyn Le Grice said she was thrilled to have the opportunity to work more closely with Mr Duchini as ANDHealth continues to build capability, investment and success across Australia’s evidence-based digital and connected health sector.

“Our fully independent Board is a critical element in ANDHealth’s continuing success. Sergio’s appointment further strengthens the strategic firepower of ANDHealth at Board level as we continue to expand our impact within Australia’s digital and connected health technology sector.”

Mr Duchini joins Alcidion Group Managing Director Kate Quirke and leading investor, adviser and entrepreneur Dr Charlie Day as Non-Executive Directors of ANDHealth, along with ANDHealth Chair Gavin Fox-Smith.